Predictive factors for a long-term response duration in non-squamous cell lung cancer patients treated with pemetrexed

Background Pemetrexed is widely used for the treatment of advanced non-squamous non-small-cell lung cancer (NSCLC). However, factors that can predict the benefits of pemetrexed therapy have not yet been defined.